LGMD DAY ON THE HILL DOWNLOADABLES

---

"Introducing a New Limb-girdle Muscular Dystrophy Natural History Study"

On Friday, September 11th, 2020 (from 12pm—1pm EST) Sarepta Therapeutics presented their new natural history study for the limb-girdle muscular dystrophy community during this online simulcast webinar hosted by the Speak Foundation. This natural history study will begin enrolling participants this summer, and Sarepta will provide an overview of the natural history study in addition to resources to stay connected to community resources and updates during this webinar.

Find Out More About Sarepta Therapeutics:

• Genetic Testing: Links to free genetic testing resources may be found on limbgirdle.com
• Staying Connected: If you are a resident of the United States and wish to stay updated on Sarepta’s work, please sign-up here:  https://limbgirdle.com/stay-connected/
• Connecting with Sarepta Patient Affairs: If you wish to connect to someone from the Sarepta Patient Affairs team, email: advocacy@sarepta.com. 

Sarepta Therapeutics is a global biotechnology company on an urgent mission to engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases, including Limb-girdle muscular dystrophy. Sarepta’s current 6 programs focus on: sarcoglycans (LGMD 2C, LGMD 2D, LGMD 2E), dysferlin (LGMD 2B), anoctomin 5 (LGMD 2L), and calpain-3 (LGMD 2A). For genetic testing information and other resources, please visit LimbGirdle.com.